Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects.

Antimicrobial agents and chemotherapy - 1 May 2012

Zala Carlos, St Clair Marty, Dudas Kathleen, Kim Joseph, Lou Yu, White Scott, Piscitelli Steve, Dumont Etienne, Pietropaolo Keith, Zhou Xiao-Jian, Mayers Douglas

Abstract excerpt

GSK2248761 is a novel, once-daily (QD), next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) with activity against efavirenz-resistant strains. Two phase I/IIa, double-blind, randomized, placebo-controlled studies investigated the antiviral activity, safety, and pharmacokinetics (PK) of several doses of GSK2248761 monotherapy in treatment-naive HIV-infected subjects. In the initial study, 10...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Argentina

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzoxazines

Share to Cyclopropanes

Share to Double-Blind Method

Share to Drug Administration Schedule

Share to Drug-Related Side Effects and Adverse Reactions

Share to Placebos

Source

Open in PubMed Open full text

Identifiers

PMID: 22314532
DOI: 10.1128/AAC.05597-11
PMCID: PMC3346662

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects.PMID 22314532Read ↗

Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor.Semantic proximity Read ↗

Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.Semantic proximity Read ↗

Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.Semantic proximity Read ↗

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.Semantic proximity Read ↗

Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients.Semantic proximity Read ↗

Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.Semantic proximity Read ↗

MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosingSemantic proximity Read ↗

Pharmacokinetics, pharmacodynamics, efficacy and drug resistance selection of injectable long-acting lenacapavir pre-exposure prophylaxis (PrEP) against HIVSemantic proximity Read ↗

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.Semantic proximity Read ↗

A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.Semantic proximity Read ↗

A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.Semantic proximity Read ↗

Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.